2019
Assessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University.
Rinehardt H, Morgan E, Kassem M, Palettas M, Miah A, Alnahhas I, Guillermo Prieto Eibl P, Suresh A, Ganju A, Williams N, Puduvalli V, Giglio P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. Assessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University. Journal Of Clinical Oncology 2019, 37: e13554-e13554. DOI: 10.1200/jco.2019.37.15_suppl.e13554.Peer-Reviewed Original ResearchDiagnosis of LCMagnetic resonance imagingLeptomeningeal carcinomatosisLMC diagnosisOverall survivalMRI findingsPrimary cancerLung cancerBreast cancerOhio State University Comprehensive Cancer CenterStage IV breast cancerSingle-institution retrospective studyCentral nervous system malignanciesMedian overall survivalStage II diseaseStage III diseaseStage IV diseaseHigh-risk patientsKaplan-Meier methodPrimary breast cancerSurvival of patientsNervous system malignanciesCerebrospinal fluid cytologyConfirmation of diagnosisComprehensive cancer center
2012
Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy
Garcia-Villa A, Balasubramanian P, Miller B, Lustberg M, Ramaswamy B, Chalmers J. Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy. Frontiers In Oncology 2012, 2: 128. PMID: 23112954, PMCID: PMC3480704, DOI: 10.3389/fonc.2012.00128.Peer-Reviewed Original ResearchStage IV breast cancerTumor cellsBreast cancer patientsPlatinum-based therapySolid tumor malignanciesPotential of CTCsSurface markers CD45Γ-H2AXDNA-damaging therapiesΓ-H2AX levelsPlatinum therapyPeripheral bloodCancer patientsPredictive markerPatient outcomesPrognostic markerBreast cancerΓ-H2AX stainingPatient's conditionTumor malignancyTherapyNegative depletionLiquid biopsyStaining patternCell apoptosis